GlassScriptPhysician profile
Omar A Geada
NPI 1861568933
$2,623.11
in general payments reported to CMS, 2019-2025
17 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $318 · 2021: $337 · 2022: $362 · 2023: $391 · 2024: $593 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.39 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $897.58 | 2019-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $482.79 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $221.80 | 2020-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $210.61 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $193.45 | 2021-2024 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.37 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $118.33 | 2021-2022 | |
| Daiichi Sankyo INC. | $70.36 | 2020-2024 | Injectafer |
| Abbvie INC. | $54.13 | 2024-2025 | |
| Glaxosmithkline, LLC. | $52.31 | 2022-2024 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $49.74 | 2024 | Inspire |
| Novartis Pharmaceuticals Corporation | $35.57 | 2019-2021 | |
| Mylan Specialty L.P. | $29.98 | 2021 | |
| Dexcom, INC. | $21.12 | 2021 | |
| Sanofi Pasteur INC. | $19.52 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $15.06 | 2020 | |
| Exact Sciences Corporation | $14.39 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Geada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.